KEDI Global Longevity Bio Index

Current President & CEO Christophe Weber is scheduled to retire and will be succeeded by CEO-elect Julie Kim on June 24, 2026. This leadership change is estimated to have a high price impact of at least 10% due to potential shifts in corporate strategy and is expected.

U.S. FDA decision on the supplemental application for LEQEMBI IQLIK on 2026-05-24; price impact is estimated to be ≥10% as a major drug catalyst, expected.

Annual Meeting of Stockholders on May 15, 2026. Annual meetings usually have minor impact on stock price, estimated at >1%, scheduled.

Full-year financial results for fiscal year 2025 are scheduled for May 13, 2026. This annual earnings release is estimated to have a medium price impact of at least 5% based on historical volatility and is expected.

Viatris is scheduled to report its first quarter 2026 financial results on May 7, 2026, with a webcast for investors scheduled. Earnings releases typically result in 5% or more price impact, so a Medium impact is expected.

The ex-dividend date for the proposed final dividend of 48.0 pence per share for the 2025 financial year is May 7, 2026. The payment date is June 18, 2026. Low importance is estimated based on typical dividend yield impact, scheduled.

Novo Nordisk is scheduled to release its Q1 2026 earnings report before the market opens on May 6, 2026, with high importance estimated due to potential 10% price impact, expected.

IQVIA Holdings will announce its first-quarter 2026 financial results before the market opens on Tuesday, May 5, 2026, with a conference call at 9:00 a.m. ET. Earnings releases can cause significant price volatility; importance is estimated as High pending results, scheduled.

Leidos first quarter 2026 financial results release and conference call for 2026-05-05, with high importance estimated due to potential for significant price impact, scheduled.

Q1 2026 earnings release scheduled. Analysts forecast EPS of approximately $0.72-$0.73 estimated. Importance is estimated as Medium as earnings reports typically drive price movements of at least 5% expected.

Q1 2026 earnings release, estimated to have a medium market impact as a recurring major financial disclosure, scheduled.

Moderna is scheduled to report its first quarter 2026 financial results and provide a corporate update on May 1, 2026, before the U.S. market opens, scheduled. High importance is estimated as earnings releases for high-volatility biotech stocks often result in ≥10% price swings.

Bristol-Myers Squibb is scheduled to report its Q1 2026 financial results on April 30, 2026, with analysts forecasting EPS of $1.45. High impact is estimated as quarterly earnings are major market catalysts scheduled.

Eli Lilly is scheduled to announce its first-quarter 2026 financial results on April 30, 2026, followed by a conference call. High impact is estimated due to significant market focus on GLP-1 sales growth scheduled.

Merck & Co. is scheduled to release its Q1 2026 earnings on April 30, 2026; impact is estimated as neutral pending the actual report, scheduled.

Alnylam is scheduled to report its financial results for the first quarter of 2026 before the U.S. financial markets open; Medium importance is estimated as earnings releases typically trigger significant volatility, scheduled.

Amgen is expected to report its Q1 2026 financial results after the market closes on April 30, 2026, scheduled. Analysts estimate a Low impact (~1-2%) as a standard scheduled reporting event, scheduled.

First-quarter 2026 financial results conference call on April 30, 2026, scheduled.

AbbVie first quarter 2026 earnings release is scheduled for April 29, 2026.

Biogen's first-quarter 2026 financial results report on 2026-04-29; price impact is estimated to be ≥5% based on historical volatility, scheduled.

GSK is scheduled to announce its first quarter 2026 financial results on April 29, 2026, scheduled.

First quarter 2026 financial results and webcast are scheduled for April 29, 2026. Medium importance estimated due to potential for significant guidance updates.

Regeneron is scheduled to report its first quarter 2026 financial and operating results on April 29, 2026, before market open. This event is expected to have a medium market impact as earnings releases typically cause significant price volatility, scheduled

Teva Pharmaceutical is scheduled to release its first quarter 2026 financial results on April 29, 2026, followed by a conference call. Medium importance is estimated based on historical earnings volatility, and the event is scheduled.

AstraZeneca's Q1 2026 results announcement is scheduled for April 29, 2026 scheduled

Novartis is scheduled to report Q1 2026 results on 2026-04-28; analysts forecast EPS of about USD 2.10, making this a near-term earnings catalyst with estimated low neutral impact until results are released. scheduled

Sanofi is scheduled to release its Q1 2026 financial results before the market opens on April 23, 2026. Analysts forecast earnings of $0.9330 per share and revenue of $10.8086 billion. This event is expected to have a medium market impact as quarterly earnings typically drive significant price movement scheduled.

Q1 2026 earnings release scheduled.

First quarter 2026 financial results to be reported after market close on April 22, 2026. Earnings releases typically cause significant price movement, estimated at >5%, scheduled.

Abbott announced Q1 2026 results, beating revenue estimates but lowering its full-year 2026 adjusted EPS forecast to $5.38-$5.58, citing $0.20 of dilution from the Exact Sciences acquisition.

Eli Lilly is expected to announce Foundayo's heart safety trial results and the FDA's request for additional data on April 16, 2026. Medium impact is estimated based on the clinical significance of obesity treatments expected.

IQVIA Holdings shares fell 2% on April 16, 2026, after OpenAI announced a new AI model for life sciences research, perceived as potential competition.

Sold the gene-therapy asset botaretigene sparoparvovec (bota-vec) to MeiraGTx on 2026-04-16 as part of a portfolio management strategy. Low importance as the divestiture of a single asset is estimated to have a 1-5% price impact; expected.

Leidos announced a joint venture with investment firm Altaris on 2026-04-15, combining its Security Enterprise Solutions (SES) business with Analogic to form a new company.

Johnson & Johnson reported Q1 2026 financial results on 2026-04-14, beating revenue and EPS estimates (analysts forecast) and raising guidance. High importance due to projected >10% price impact from strong performance; expected.

Novo Nordisk and OpenAI announced a strategic partnership on April 14, 2026, to integrate advanced AI for discovering and delivering new medicines.

On April 14, 2026, the U.S. FDA refused to file partner Replimune's application for RP1 in combination with Opdivo for advanced melanoma due to study design concerns.

Announced a 3.1% increase in its quarterly dividend to $1.34 per share on 2026-04-14, marking the 64th consecutive year of increases. Low importance as the dividend increase is likely to result in a 1-5% price impact; expected.

The FDA approved the first generic versions of AstraZeneca's blockbuster Type 2 diabetes drug, Farxiga, on April 13, 2026. This will introduce significant competition and likely lead to sales erosion.

On April 13, 2026, AbbVie entered into an exclusive license agreement with Haisco Pharmaceutical to develop and commercialize a portfolio of novel pain compounds.

The U.S. FDA granted Priority Review for the Biologics License Application for ifinatamab deruxtecan for a type of small cell lung cancer on April 13, 2026. The PDUFA action date is set for October 10, 2026.

On April 13, 2026, Regeneron and Telix Pharmaceuticals announced a strategic collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies for cancer with a $40 million upfront payment

On April 13, 2026, the European Commission approved Dupixent (dupilumab), developed with Regeneron, to treat children aged 2 to 11 with moderate-to-severe chronic spontaneous urticaria (CSU).

On April 13, 2026, the European Commission approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged two to 11

Announced a strategic data collaboration between its PPD clinical research business and HealthVerity.